Cephalon On Track To File Treanda For Second Cancer Indication By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.